Julia E Maxson

List of Publications by Year
in descending order

24 papers	1,084 citations	623734 14 h-index	713466 21 g-index
27 all docs	27 docs citations	27 times ranked	1335 citing authors

#	Article	IF	Citations
1	OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML. New England Journal of Medicine, 2013, 368, 1781-1790.	27.0	499
2	The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood, 2013, 122, 3628-3631.	1.4	95
3	Genomics of chronic neutrophilic leukemia. Blood, 2017, 129, 715-722.	1.4	74
4	Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. Leukemia Research Reports, 2014, 3, 67-69.	0.4	62
5	Ligand Independence of the T618I Mutation in the Colony-stimulating Factor 3 Receptor (CSF3R) Protein Results from Loss of O-Linked Glycosylation and Increased Receptor Dimerization. Journal of Biological Chemistry, 2014, 289, 5820-5827.	3.4	51
6	CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML. Blood, 2016, 127, 3094-3098.	1.4	49
7	The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I. Clinical Cancer Research, 2016, 22, 757-764.	7.0	40
8	Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis. Cancer Research, 2016, 76, 127-138.	0.9	31
9	Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 13670-13679.	7.1	24
10	Gain-of-function mutations in granulocyte colonyâ€“stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation. Journal of Biological Chemistry, 2018, 293, 7387-7396.	3.4	22
11	Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia. Nature Communications, 2019, 10, 5455.	12.8	22
12	Therapeutically Targetable ALK Mutations in Leukemia. Cancer Research, 2015, 75, 2146-2150.	0.9	20
13	A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia. Cancer Research, 2018, 78, 6762-6770.	0.9	17
14	Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia. Science Signaling, 2018, 11, .	3.6	16
15	Prognostic impact of CSF3R mutations in favorable risk childhood acute myeloid leukemia. Blood, 2020, 135, 1603-1606.	1.4	15
16	Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia. Leukemia, 2021, 35, 3594-3599.	7.2	15
17	TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nature Communications, 2021, 12, 5337.	12.8	14
18	PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia. Leukemia, 2022, , .	7.2	7

#	Article	IF	Citations
19	Co-Occurring CSF3R W791* Germline and Somatic T618I Driver Mutations Induce Early CNL and Clonal Progression to Mixed Phenotype Acute Leukemia. Current Oncology, 2022, 29, 805-815.	2.2	3
20	A new role for hematoxylin: targeting CALR. Blood, 2021, 137, 1848-1849.	1.4	2
21	Integrative Analysis of Drug Response and Clinical Outcome in Acute Myeloid Leukemia. SSRN Electronic Journal, 0, , .	0.4	2
22	Single Cell RNA Sequencing Identifies a Crucial Role for ASXL1 in Neutrophil Development. Blood, 2019, 134, 212-212.	1.4	1
23	Function of ASXL1 Mutations in Chronic Neutrophilic Leukemia. Blood, 2018, 132, 3067-3067.	1.4	0
24	SETBP1 Mutations Accelerate NRAS-Mutant Leukemia. Blood, 2019, 134, 1254-1254.	1.4	0